|
Surrogate Endpoints And FDA’s Accelerated Approval Process
Thomas R. Fleming
There is interest in approaches allowing more rapid availability of new interventions, particularly for diseases providing risks of death or serious illness. The accelerated-approval regulatory process is intended to address this need by allowing marketing of interventions shown to have strong effects on measures of biological activity, if those measures are potential "surrogates" for true measures of tangible clinical benefit. To use surrogate endpoints and the accelerated-approval process, challenging issues must be addressed to avoid compromising what is truly in the best interest of public health: the reliable as well as timely evaluation of an intervention’s safety and efficacy.
       What's this?
This article has been cited by other articles:
|
|
|
|
 
E. D. Saad, A. Katz, P. M. Hoff, and M. Buyse
Progression-free survival as surrogate and as true end point: insights from the breast and colorectal cancer literature
Ann. Onc.,
January 1, 2010;
21(1):
7 - 12.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Fleming, M. D. Rothmann, and H. L. Lu
Issues in Using Progression-Free Survival When Evaluating Oncology Products
J. Clin. Oncol.,
June 10, 2009;
27(17):
2874 - 2880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Piedbois and J. Miller Croswell
Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective
Statistical Methods in Medical Research,
October 1, 2008;
17(5):
519 - 527.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J Petkau, S. Reingold, U Held, G. Cutter, T. Fleming, M. Hughes, D. Miller, H. McFarland, and J. Wolinsky
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses
Multiple Sclerosis,
July 1, 2008;
14(6):
770 - 778.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. N Lassere
The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints
Statistical Methods in Medical Research,
June 1, 2008;
17(3):
303 - 340.
[Abstract]
[PDF]
|
|
|
|
|
|
|
T. R Fleming, K. Sharples, J. McCall, A. Moore, A. Rodgers, and R. Stewart
Maintaining confidentiality of interim data to enhance trial integrity and credibility
Clinical Trials,
April 1, 2008;
5(2):
157 - 167.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. C. Jaffe
Response Assessment in Clinical Trials: Implications for Sarcoma Clinical Trial Design
Oncologist,
April 1, 2008;
13(suppl_2):
14 - 18.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Pazdur
Endpoints for Assessing Drug Activity in Clinical Trials
Oncologist,
April 1, 2008;
13(suppl_2):
19 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. F. Symmans, F. Peintinger, C. Hatzis, R. Rajan, H. Kuerer, V. Valero, L. Assad, A. Poniecka, B. Hennessy, M. Green, et al.
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
J. Clin. Oncol.,
October 1, 2007;
25(28):
4414 - 4422.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. P. Rock, J. A. Scott, D. L. Kennedy, R. Sridhara, R. Pazdur, and L. B. Burke
Challenges to Use of Health-Related Quality of Life for Food and Drug Administration Approval of Anticancer Products
J Natl Cancer Inst Monographs,
October 1, 2007;
2007(37):
27 - 30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mayer-Hamblett, B. W. Ramsey, and R. A. Kronmal
Advancing Outcome Measures for the New Era of Drug Development in Cystic Fibrosis
Proceedings of the ATS,
August 1, 2007;
4(4):
370 - 377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Schuster
The Opportunities and Challenges of Developing Imaging Biomarkers to Study Lung Function and Disease
Am. J. Respir. Crit. Care Med.,
August 1, 2007;
176(3):
224 - 230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Sorensen
Magnetic Resonance As a Cancer Imaging Biomarker
J. Clin. Oncol.,
July 10, 2006;
24(20):
3274 - 3281.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Neumann
Emerging Lessons From The Drug Effectiveness Review Project
Health Aff.,
July 1, 2006;
25(4):
W262 - W271.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Starfield
Threads and Yarns: Weaving the Tapestry of Comorbidity
Ann. Fam. Med,
March 1, 2006;
4(2):
101 - 103.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi
Iron Chelation Therapy for Myelodysplastic Syndrome: If and When
Mayo Clin. Proc.,
February 1, 2006;
81(2):
197 - 198.
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. C. Johnson and G. Raghu
Clinical trials in idiopathic pulmonary fibrosis: a word of caution concerning choice of outcome measures
Eur. Respir. J.,
November 1, 2005;
26(5):
755 - 758.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. R. Fleming
Objective Response Rate As a Surrogate End Point: A Commentary
J. Clin. Oncol.,
August 1, 2005;
23(22):
4845 - 4846.
[Full Text]
[PDF]
|
|
|
|
